Corpus Intelligence IC Memo — SPRING MOUNTAIN TREATMENT CENTER 2026-04-26 06:40 UTC
IC Memo — SPRING MOUNTAIN TREATMENT CENTER
Investment Committee Memorandum | NV | 110 beds | Grade C | EBITDA uplift $1.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SPRING MOUNTAIN TREATMENT CENTER

CCN 294011 | nan, NV | 110 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SPRING MOUNTAIN TREATMENT CENTER is a 110-bed suburban community hospital in nan, NV with $16.8M in net patient revenue and a 0.8% operating margin. The hospital serves a payer mix of 7.3% Medicare, 10.4% Medicaid, and 82.3% commercial.

Thesis: Undervalued. Our ML models identify $1.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 0.8% to 8.1% (+736bps).

Net Revenue HCRIS$16.8M
Current EBITDA COMPUTED$126K
Operating Margin COMPUTED0.8%
Occupancy HCRIS58.8%
Revenue / Bed COMPUTED$153K
Net-to-Gross HCRIS35.7%
Distress Probability ML49.0%

2. Market Context & Competitive Position

58
NV Hospitals
0.4%
State Median Margin
21
Comparable Hospitals

NV has 58 Medicare-certified hospitals with a median operating margin of 0.4%. The target's margin of 0.8% places it above the state median. Among 21 size-comparable peers (55-220 beds), the median margin is 0.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (55-220), prioritizing same-state peers. 21 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SPRING MOUNTAIN TREATMENT CENT (Target)NV110$16.8M0.8%
CARSON TAHOE REGIONAL HEALTHCANV175$365.4M3.0%
SOUTHERN HILLS HOSPITAL & MEDINV205$317.7M11.7%
DESERT SPRINGS HOSPITAL MEDICANV190$182.8M-39.4%
ST. ROSE DOMINICAN - SAN MARTINV130$179.5M-18.6%
NORTHERN NEVADA MEDICAL CENTERNV88$150.8M10.5%
NORTH VISTA HOSPITALNV163$117.3M9.5%
RENOWN SOUTH MEADOWS MED CTRNV78$91.0M4.0%
NORTHEASTERN NEVADA REGIONAL HNV59$84.2M15.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$353K+210bp18mo
Cost to Collect4.5%2.5%$337K+200bp12mo
Denial Rate Reduction12.0%6.5%$333K+198bp12mo
A/R Days Reduction5200.0%3800.0%$205K+122bp9mo
Clean Claim Rate88.0%96.0%$11K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$353K
Cost to Collect
$337K
Denial Rate Reduction
$333K
A/R Days Reduction
$205K
Clean Claim Rate
$11K
Total EBITDA Uplift$1.2M
Current EBITDA$126K
+ RCM Uplift+$1.2M
Pro Forma EBITDA$1.4M
Current Margin0.8%
Pro Forma Margin8.1%
WC Released (1x)$646K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$194K$13.2M68.05x132.6%
Base (11x exit)10.0x11.0x$194K$14.6M75.18x137.3%
Bull Case9.0x11.0x$175K$18.8M107.27x154.7%
Bull (12x exit)9.0x12.0x$175K$20.5M117.32x159.3%
Bear Case11.0x10.0x$214K$7.0M32.58x100.7%
Bear (11x exit)11.0x11.0x$214K$7.7M36.17x105.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 21 hospitals with 55-220 beds
  • Same-state prioritization (n=22)
  • Comp margins: P25=-18.6% / P50=0.1% / P75=10.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.